Imaging agent developer FluoroPharma has begun phase I clinical trials for a myocardial perfusion imaging (MPI) tracer for PET imaging, according to its parent company, QuantRx Biomedical of Doylestown, PA.
The trial is a single-center, open-label study that will evaluate safety, distribution, and dosimetry of the tracer, BFPET, for MPI imaging in healthy subjects. If successful, BFPET will improve coronary artery disease diagnosis and follow-up, and increase PET's utility, according to Boston-based FluoroPharma.
Related Reading
Boston Life Sciences ends FluoroPharma deal, July 27, 2005
Copyright © 2008 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
